CINCINNATI, Ohio, December 16, 2024 / BUSINESS WIRE / — LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration…Original Article
LIB Therapeutics Submits a Biologics License Application to FDA for Lerodalcibep for the Treatment of Adults with Elevated LDL-Cholesterol
